![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 28, 21572-21577, July 14, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, April 3, 2000, and in revised form, April 27, 2000
The three-dimensional structure of the major
horse allergen Equ c 1 has been determined at 2.3 Å resolution by
x-ray crystallography. Equ c 1 displays the typical fold of lipocalins,
a The incidence of allergic diseases is increasing in developed
countries resulting from growing exposure to allergens, altered stimulation of the immune system during development, and probably facilitating an adjuvant effect of the environment. Allergy to animals
is distinguishable by its intensity and the possibility of
sensitization by a limited contact with danders or hair. The animals
responsible for allergy are obviously familiar domestic cats and dogs,
but also the horse, which is often incriminated. Five main horse
allergens have been isolated and purified (1, 2). Among these, the Equ
c 1 protein (molecular mass 21.5 kDa, 187 amino acids, pI = 4.5)
has been defined as a major allergen, because it induces an
IgE-mediated type I allergic reaction in a majority of the patients
allergic to horses.
Equ c 1 belongs to the lipocalin family (3, 4). Although members of
this family display low sequence similarity (often lower than 20% of
amino acid identities), all share a conserved folding pattern, an
8-stranded Whether a protein exhibits special structural characteristics that are
responsible for its allergenic properties is an issue that remains
poorly understood. Although the three-dimensional structures of some
allergenic lipocalins are known (mMUP (9), rat urinary Crystallization and Data Collection--
Protein expression,
purification, and crystallization of recombinant sublingual gland
(rSLG) Equ c 1 have been previously described (3, 4). Briefly, rSLG Equ
c 1 was expressed as a His-tagged protein in Escherichia
coli, purified by metal-ion affinity chromatography, treated with
factor Xa to excise the His tag, and concentrated to 6.0 mg/ml for
crystallization. Tetragonal bipyramidal crystals, space group
P41212, were grown at 291 K using the hanging
drop vapor diffusion technique (4). A first diffraction data set (with
an overall R-merge value of 8.9%) was collected at 2.9 Å resolution from a flash-frozen (110 K) crystal using synchrotron
radiation at EMBL/DESY (Hamburg). Subsequently, a second data set was
recorded at room temperature to a higher (2.3 Å) resolution using the
X31 beamline at EMBL/DESY ( Structure Determination and Refinement--
The structure was
solved by molecular replacement methods using the program AMoRe (21).
The atomic coordinates of the mouse mMUP protein (PDB code 1MUP) (9),
which shares 49% of sequence identity with Equ c 1 (Fig. 1), was used
as the search model. A clear solution was obtained using the low
temperature data set, with a correlation coefficient of 0.39 and a
crystallographic R-factor of 48.7%. Initial rigid body
refinement was carried out with the program XPLOR (22), followed by 31 cycles using the slow cool protocol of XPLOR for all reflections with
F > 3
The current model was then positioned in the room temperature unit cell
by molecular replacement, and further crystallographic refinement was
carried out against the 2.3 Å data set obtained at room temperature
using the maximum likelihood refinement program REFMAC (23) from the
CCP4 package (24). At each stage of the refinement, errors in the model
were detected by examination of (Fo - Fc) and (2Fo - Fc) maps with the program O (25). Toward the end
of the refinement the whole polypeptide chain could be traced
unambiguously in the electron density map, and 79 water molecules were
added to the protein model using the program ARP (26). Refinement
converged to a final R-factor of 19.5% (free R-factor = 25.2%) for intensities between 15 and 2.3 Å (Table I). The average real space correlation coefficient for all
main chain atoms of the final model is 0.95 (0.89 for side-chain
atoms). The atomic coordinates of Equ c 1 have been deposited with the Protein Data Bank (code 1EW3).
Site-directed Mutagenesis--
Four point mutants of rSLG Equ c
1 (R26S, E82A, K129S, and E148A) were produced by polymerase chain
reaction-based site-directed mutagenesis using two common primers
derived from the sequence of the pGEX plasmid (P5'rac,
5'-GGCAAGCCACGTTTGGTG-3' and P3'rac, 5'-CCGGGAGCTGCATGTGTC-3') and one
mutagenic primer for each single mutant (5'-ATCGAAGTTGCTTATCGCAACATC-3'
for R26S, 5'-TCAGTACACGCTCCATTTACC-3' for E82A,
5'-GGAATGGTCTGTCGCTGTCGAAATTC-3' for K129S, and
5'-CTTCCTTGATTGCTGGACTCACATC-3' for E148A). Inserts containing no
additional mutation were selected and subcloned into the
EcoRI/XhoI sites of the pET 28 (a) plasmid. Bacterial expression in E. coli BL21 (DE3) and protein
purification of each rSLG Equ c1 point mutants were performed as
described before (3 and 4).
Production and Binding of Monoclonal
Antibodies--
Eight-week-old Balb/c mice were injected three times
with natural Equ c 1. Conventional procedures were used to fuse immune spleen cells to SP2/0 cells with polyethylene glycol, and specific IgG-secreting hybridomas were then selected after screening of the
supernatants. For ELISA screenings, purified Equ c 1 molecule, either
natural (from horse dander extract) or recombinant (wild-type or point
mutants), was coated at 10 µg/ml in 0.1 M
carbonate/bicarbonate buffer, pH 9.6, in 96-well microtitration plates.
After saturation with 0.5% bovine serum albumin, serial concentrations
of mouse mAb (0.01 to 100 µg/ml), rabbit polyclonal Ab (0.01 to 100 µg/ml), or human serum IgE (1/2 to 1/100) were added in duplicate or
triplicate to each well and incubated at 37 °C during 1 h 30 m.
Binding was revealed with peroxidase-labeled goat anti-mouse IgG, goat
anti-rabbit Ig, or biotinylated goat anti-human IgE + peroxidase-coupled streptavidin, respectively, followed by
o-phenylenediamine according to the manufacturer's recommendations.
Competitive experiments were performed by co-incubating serial
dilutions of the competitor Ab (0.1 to 100 µg/ml) with a
predetermined concentration of the anti-Equ c 1 Ab biotinylated (for
the experiments reported in Fig. 4) or not (for the experiments
reported in Fig. 5) in Equ c 1-coated microtitration plates. Residual
binding was revealed with peroxidase-labeled streptavidin or
appropriate peroxidase-labeled secondary Ab, respectively.
The Overall Structure of Equ c 1--
The final model of the Equ c
1 monomer (Fig. 2a) includes 159 amino acid residues (from
Ala23 to Gly181). The final parameters of
refinement and model stereochemistry are summarized in Table
I. Only the solvent-exposed side chain of
Arg131 in a surface loop was not visible in the electron
density map and was modeled as alanine, although other exposed amino
acid residues (Arg26, Asp67, Glu82,
Glu94, Glu148, and Glu165) also
display very high temperature factors for their side-chain atoms. All
but one nonglycine and nonproline residues (99.3%) have main-chain
dihedral angles which fall within allowed regions of the Ramachandran
diagram, as defined by PROCHECK (27). The outlier Glu115
(
The overall structure of Equ c 1 is similar to that of other lipocalins
(6-9, 17-19, 29-32), an 8-stranded The Equ c 1 Dimer--
Equ c 1 is found to form a dimer in the
crystal, in agreement with gel filtration experiments in solution at
neutral pH (4). The crystallographic dimer is formed by the
side-to-side packing of the
Although monomeric forms of lipocalins have been characterized (such as
the allergen Bos d 2 (19), the retinol-binding protein (8), or the
human neutrophil gelatinase-associated protein (31)), lipocalins often
exist as dimers or higher oligomers. However, no consistent pattern of
dimerization is obvious from the analysis of known three-dimensional
structures. Indeed, the mode of dimerization of Equ c 1 has not been
previously observed in other lipocalin dimers studied by x-ray
diffraction (Fig. 3). In mMUP, the dimer
interface includes the The Putative Ligand Binding Site--
The biological role of Equ c
1 is unknown. As in most proteins belonging to the lipocalin family,
its physiological role might be concerned with the binding and
transport of small hydrophobic ligands. The internal space between the
two
The partially helical L1 loop connecting Restricted IgE Epitopes--
To gain further insight into putative
regions of the Equ c 1 molecule that might define B cell epitopes, mAbs
were raised in Balb/c mice immunized with natural Equ c 1 purified from
horse hair dander extract (3). Four hybridomas were selected for the
secretion of specific antibodies (IgG1,
Analysis of the overall structure of the Equ c 1 monomer revealed four
protruding, solvent-accessible regions that could determine putative
targets for antibody binding (35). Charged amino acid residues
belonging to these regions were substituted by site-directed mutagenesis: R26S, E82A, K129S, and E148A (see Fig. 6). The four point
mutants of rSLG Equ c 1 exhibited the same molecular weight as
evaluated from SDS-polyacrylamide gel electrophoresis (molecular mass
19.5 kDa) and isoelectric point (pI 4.5) than the unmutated form (data
not shown). Their immunoreactivity, as compared with natural and
recombinant wild-type Equ c 1, was tested in direct binding ELISA with
the four available anti-Equ c 1 mAbs and human IgE from various horse
allergic patients (Table IV). Mouse mAb 65 (which binds to natural glycosylated Equ c 1 but not to recombinant wild-type Equ c 1) failed to recognize all four Equ c 1 mutants, thus
confirming that protein-bound carbohydrate should be part of the mAb 65 epitope. The other three mAbs (118, 197, and 220) and the IgE serum
were able to recognize all four point mutants as evaluated from direct
ELISA, with only one exception; mAb 197 failed to react with E82A. This
lack of binding further supported the hypothesis that the L3 loop is
part of the mAb 197 epitope and is also consistent with the absence of
reactivity of this mAb to reduced natural Equ c 1 (Table III), the
substitution at position 82 being close to one of the cysteine residues
involved in the intramolecular disulfide bridge
(Cys83-Cys176) of Equ c 1.
To further delineate putative epitopes recognized by human serum IgE
from horse allergic patients, competitive experiments were performed
with the four anti-Equ c 1 mAbs. Serial dilutions of competitor
antibody, either rabbit polyclonal (used as control inhibitor) or mouse
monoclonal, were incubated with natural or recombinant-coated Equ c 1 together with individual human serum IgE. As expected, the binding of
IgE serum from a representative patient (similar results were
reproduced with IgE serum from various horse allergic patients taken
individually) was totally inhibited by the anti-Equ c 1 rabbit
polyclonal Ab, which should contain a complete spectrum of antibodies
directed against various regions of Equ c 1 (Fig.
5). No inhibition of IgE binding was
noticed with mAbs 118 or 197, whereas mAb 65 could partially inhibit
recognition of natural Equ c 1 (Fig. 5A), suggesting that
some IgE epitopes overlap with the glycosylated epitope recognized by
mAb 65. More interestingly, total inhibition of serum IgE binding to
either natural or recombinant Equ c 1 was observed with mAb 220, indicating that the IgE-reactive epitopic regions of Equ c 1 are highly
restricted. Although conformational changes of the allergen induced by
mAb 220 could also explain the observed inhibition, such a possibility is unlikely because binding of mAb 220 to Equ c 1 did not affect the
reactivities of mAbs 197 and 118 (Fig. 4).
The allergic response is determined by a number of factors such as
the genetic background and immunological history of the individual and
the dose, mode of entry, and biochemical nature of the allergen.
Structural knowledge of allergens may therefore have considerable
impact on the generation of tools for the immunotherapy of allergic
diseases, by providing insight into the mechanisms of immune
recognition (14, 19) and the physiological role (36) of allergens.
Equ c 1 is the main major allergen in patients sensitive to horses. It
is a member of the lipocalin family of proteins that includes several
well studied allergens, such as Mus m 1 (mMUP), Bos d 2, Bos d 5 ( Equ c 1 crystallizes as a tight dimer with an extended contact surface
between monomers. Because a dimer has also been observed in solution at
neutral pH (4), it should represent the relevant form of Equ c 1 in vivo, when it interacts with the immune system of the
human host. Two putative N-glycosylation sites,
Asn53 and Asn68, can be predicted from the
amino acid sequence of Equ c 1, although analysis of the saccharide
composition of natural Equ c 1 indicated that only one of these sites
is occupied by carbohydrate (3). The three-dimensional structure of
rSLG Equ c 1 showed that the side chains of the two Asn residues are
exposed to the solvent (Fig. 6),
suggesting that in each case the covalent attachment of carbohydrate
would not interfere with either the monomer structure or dimer
formation.
Binding studies of mouse mAbs specific for Equ c 1 allowed to outline
putative B cell antigenic determinants of the allergen. The epitope
recognized by mAb 65 was shown to involve the region close to the
single glycosylation site of Equ c 1 and might coincide in part with
some IgE epitopes according to the partial inhibition of IgE binding
observed in competition experiments (Fig. 5A). On the other
hand, mAbs 118 and 197 bind to a mutually overlapping, though not
identical, region of the molecule, because both mAbs compete with each
other for binding (Fig. 4) but react differently with reduced Equ c 1 (Table III). Their corresponding epitopes probably involve residues
from the L3 loop, as indicated by the lack of binding of mAb 197 to
both the E82A mutant (close to the disulfide bridge
Cys83-Cys176) and dithiothreitol-reduced Equ c 1.
Unexpectedly, binding of IgE serum from allergic patients was totally
inhibited by a single monoclonal antibody, mAb 220 (Fig. 5). This
observation can be explained either by the overlap of the corresponding
IgE and mAb 220 epitopes or alternatively by conformational changes on
the allergen upon binding of mAb 220 that could destroy nonoverlapping
IgE epitopes somewhere else on the allergen surface. However, the
second hypothesis is unlikely, because mAb 220 binding did not affect
the reactivity of the other mouse monoclonal antibodies in competitive
assays (Fig. 4). Therefore, it follows that the dominant IgE epitopes
of Equ c 1 are circumscribed to a restricted region of the allergen
surface, which overlaps with the mAb 220 epitope. These results differ
from those found by Olson and Klapper (39), who used a similar approach
(inhibition studies with murine mAbs) to identify putative IgE binding
sites on antigen E, an allergen isolated from short ragweed pollen. These authors identified two major IgE antigenic sites in inhibition and double bind solid-phase ELISA, but in their case the binding of IgE
in pooled human serum from allergic individuals was only partially
(50%) blocked by murine mAbs specific for each epitope.
A number of observations provides further insight on candidate regions
for the putative binding targets of human IgE and mouse mAb 220 in Equ
c 1: (i) the epitopes are unlikely to include a protein-bound
carbohydrate because mAb 220 and IgE serum display a similar reactivity
for natural and recombinant Equ c 1 (Table IV and Fig. 5), (ii) the
region around the L3 loop of the allergen can also be excluded from the
epitope because mAb 197 (which binds to this region) does not compete
with IgE or mAb 220 binding (Figs. 4 and 5), and (iii) the four single
point mutations of Equ c 1 (involving in each case the substitution of
a charged residue by Ala or Ser) did not modify the reactivity of the
molecule with mouse mAb 220 or horse allergic patient IgE (Table IV),
suggesting that these amino acid residues are not part of the
corresponding epitopes. As a consequence, the highly accessible region
comprising the L2 loop and part of the adjacent A second putative target, on the opposite face of the dimer, is
provided by the first part of the C-terminal loop of the molecule (residues 158-172 following the It is possible that the IgE immune response to exogenous (nonself)
lipocalin allergens could be directed to specific binding targets on
the molecular surface (14), in agreement with the restricted nature of
B and T cell responses observed against exogenous lipocalins (40, 41).
However, very limited information is available about B-cell epitopes on
allergenic lipocalins. Rouvinen et al. (19) compared the
amino acid sequences of several lipocalin allergens and detected a
resemblance between the molecules in certain areas of the surface,
which could indicate common determinants of allergenicity. These
regions include the N- and C-terminal ends of *
This work was supported by grants from the Institut
Pasteur and CNRS (France) and the European Union for the TMR/LSF
program to the EMBL Hamburg Outstation, reference number
ERBFMGECT980134.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Present address: University of Virginia, Dept. of Medicine,
Box 225, Health Sciences Center, Charlottesville, VA 22908.
§§
To whom correspondence should be addressed: Unité de
Biochimie Structurale, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France. Tel.: (33) 1 45 68 86 07; Fax: (33) 1 45 68 86 04; E-mail: alzari@pasteur.fr.
Published, JBC Papers in Press, April 27, 2000, DOI 10.1074/jbc.M002854200
2
M.-B. Lascombe, C. Grégoire, P. Poncet,
G. A. Tavares, I. Rosinski-Chupin, J. Rabillon, H. Goubran-Botros,
J.-C. Mazié, B. David, and P. M. Alzari, unpublished data.
The abbreviations used are:
mMUP, mouse major
urinary protein (or mouse allergen Mus m 1);
IgE, type E
immunoglobulin;
rSLG, recombinant sublingual gland;
ELISA, enzyme-linked immunosorbent assay;
mAb, monoclonal antibody;
Ab, antibody.
Crystal Structure of the Allergen Equ c 1
A DIMERIC LIPOCALIN WITH RESTRICTED IgE-REACTIVE EPITOPES*
,
,
,
§§
Unité de Biochimie Structurale (CNRS
URA 2185), § Unité d'Immuno-Allergie, ** Unité
de Génétique et de Biochimie du Développement, and

Laboratoire d'Ingénierie des
Anticorps, Institut Pasteur, 25 et 28 rue du Docteur Roux,
75724 Paris Cedex 15, France
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-barrel flanked by a C-terminal
-helix. The space between the
two
-sheets of the barrel defines an internal cavity that could
serve, as in other lipocalins, for the binding and transport of small
hydrophobic ligands. Equ c 1 crystallizes in a novel dimeric form,
which is distinct from that observed in other lipocalin dimers and
corresponds to the functional form of the allergen. Binding studies of
point mutants of the allergen with specific monoclonal antibodies
raised in mouse and IgE serum from horse allergic patients allowed to identify putative B cell antigenic determinants. In addition, total
inhibition of IgE serum recognition by a single specific monoclonal
antibody revealed the restricted nature of the IgE binding target on
the molecular surface of Equ c 1.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-barrel flanked by an
-helix at the C-terminal end of
the polypeptide chain. The lipocalin
-barrel often defines a central
apolar cavity that serves for the binding and transport of small
hydrophobic molecules such as retinol (retinol-binding protein (5, 6)),
odorant molecules (bovine odorant-binding protein (7, 8)), or
pheromones (mouse major urinary protein,
mMUP1 (9), and rat urinary
2-globulin (10)). Several lipocalins have been described as
allergenic proteins, among which the mouse major urinary protein mMUP
(11), rat urinary
2-globulin rat urinary
2-globulin (12), bovine
-lactoglobulin (13), cockroach allergen Bla g 4 (14), dog allergens
Can f 1 and Can f 2 (15), and bovine allergen Bos d 2 (16).
2-globulin
(10), bovine
-lactoglobulin (17, 18), and Bos d 2 (19)), little
information is available about the nature of the B epitopes recognized
by the IgE immunoglobulins. It has been suggested that allergenic
proteins may share some common structural features capable of eliciting
an IgE response (14) and also that sequence similarities between
allergenic lipocalins could indicate putative IgE binding regions (19). To gain further insight into the nature of the IgE B epitopes, we
describe here a crystallographic and immunochemical study of recombinant Equ c 1. The three-dimensional structure of the protein has
been determined at 2.3 Å resolution, and binding studies of Equ c 1 surface mutants by specific monoclonal antibodies provided valuable
information to map the Equ c 1 antigenic determinants and to delineate
the regions of the protein surface primarily recognized by IgE serum
from allergic patients.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
= 1.2 Å) from a capillary-mounted
crystal (the statistics of data collection are shown in Table I). All
diffraction data were processed with the programs DENZO and SCALEPACK
(20). The unit cell parameters measured at room temperature
(a = b = 84.04 Å, c = 58.48 Å) are slightly different from those found for the frozen
crystal (a = b = 84.36 Å,
c = 54.89 Å). In particular, the significant shrinkage (8%) of the c parameter upon flash freezing of the crystal
could be related with the loss of diffracting power of the crystal at low temperature.
(F) between 10 and 2.9 Å resolution. At this stage
(R-factor = 27.5%, free R-factor = 37.9%), the L3 loop involving residues 82-86 and the C-terminal end
of the protein (beyond the long
-helix) were not visible in the
electron density map.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
= 70.3°,
=
35.6°), is located in the exposed L6
loop, a structurally conserved region in lipocalins (28), which often displays unfavorable main-chain conformations (18).
Crystallographic data and refinement statistics for the Equ c 1 structure
-barrel flanked by an
-helix. In Equ c 1, there is a short additional
-strand and one
helical turn at the C-terminal end of the polypeptide chain. A
conserved disulfide bridge links Cys83 in loop L3 with
Cys176 at the C-terminal region of the chain. As in most
lipocalins, the
-barrel defines an internal cavity, which can
accommodate a small hydrophobic ligand. Loops L2 (connecting
B-
C), L4 (
D
E), and L6 (
F
G) define the
"closed" end of the
-barrel, whereas loops L1 (partly helical),
L3, and L5 form the entry site for ligand binding (Fig. 2). The protein
backbone of the horse allergen is structurally similar to that of the
mouse allergen mMUP (9), with an overall root mean square deviation
between main-chain atoms of 1.124 Å (Figs.
1 and 2b). In particular, the
core of the structure (the two
-sheets and the
-helix) and the
long L1 loop, which partially closes the ligand entry site, are well conserved. The most important differences between the two structures involve the N- and C-terminal ends of the polypeptide chain. Minor, but
significant, differences are also observed for loops L2 (which includes
a single amino acid insertion in Equ c 1, see Fig. 1), L3, L6, and L7
(Fig. 2b).

View larger version (23K):
[in a new window]
Fig. 1.
Sequence alignment between Equ c1 and mMUP,
which share 49% of identical amino acid residues. The elements of
secondary structure (
-helix and
-strands A-H) and connecting
loops are indicated above the sequence. Amino acid residues contacting
the pheromone ligand in mMUP are boxed.

View larger version (79K):
[in a new window]
Fig. 2.
a, overall structure of the Equ c 1 monomer. The disulfide bridge Cys83-Cys176 is
shown in ball-and-stick style. b, superposition of the C
backbones of mMUP (white) and Equ c 1 (gray).
C, drawing of the Equ c 1 crystallographic dimer. The
contact surface between the two monomers is primarily composed of
-strands F, G, and H from each monomer. D, front view of
the dimer interface (this view is rotated 90° from that shown in
c). The hydrophobic patch of residues at the center of the
contact surface is shown in black, whereas hydrophilic or
polar amino acids are shown in light gray.
-barrels through the interaction of
strands
F,
G, and
H from each monomer, with the two
-helices on the same side of the dimer and running antiparallel to
each other (Fig. 2c). The entry sites to the putative
binding sites of Equ c 1 (loops L1, L3, and L5) are located on opposite
sides of the dimer and are accessible for ligand binding. The tight
association buries 1070 Å2 of exposed molecular surface
from each monomer (as calculated with the program DSSP (33)), which
represents 13% of the total solvent accessible surface (8300 Å2). Such an extended contact surface suggests that the
dimerization state observed in the crystal is physiologically relevant.
The center of the contact surface is composed by an extended
hydrophobic patch including aliphatic and aromatic side-chains
(Ile25, Val46, Val98,
Val108, Phe109, Ile111,
Val125, Phe127, and Phe133) (Fig.
2d). Toward the periphery of the interface, hydrophilic amino acids are also involved in dimer formation (Arg26,
Asn27, Asp45, Thr93,
Glu94, Glu95, Asn102,
Tyr106, Arg110, Tyr123,
Asp128, Lys129, Asp130,
Pro132, Glu134, Lys159, and
Arg160).
-sheet composed of strands B, C, and D, and
two Cd2+ ions (9), whereas bovine
-lactoglobulin
dimerizes by joining the first
strand and the L1 loop of each
monomer (17), and dimerization of the odorant-binding protein involves
the swapping of the
-helix between the two monomers (7, 8).

View larger version (62K):
[in a new window]
Fig. 3.
Different modes of lipocalin
dimerization. a, Equ c 1 (view rotated 90° around a
horizontal axis from that shown in Fig. 2c); B,
bovine
-lactoglobulin (PDB entry code 1BEB (18)); C,
bovine odorant-binding protein (PDB entry code 1OBP (8)); D,
mMUP (PDB entry code 1MUP (9)). For each protein, one monomer (in
light gray) is shown in a similar orientation, except for
mMUP, which has been slightly rotated for clarity. This figure was
produced with the program MOLSCRIPT (42).
-sheets of Equ c 1 defines a hydrophobic pocket similar to that
observed for mMUP. Indeed, amino acid residues that are in contact with
the pheromone ligand in mMUP are also well conserved in Equ c1 (Fig.
1). The mMUP residues Leu44, Val58,
Phe60, Phe94, Ala107,
Leu109, Leu120, and Tyr124, are
replaced in Equ c 1 by Val58, Ala73,
Tyr75, Phe109, Leu122,
Leu124, Leu135, and Tyr139,
respectively. The presence of the additional hydroxyl group of
Tyr75 in Equ c 1 (Phe60 in mMUP) is compensated
by the smaller volume occupied by the neighboring residues
Ala73 and Val58 (Val58 and
Leu44 in mMUP), therefore suggesting that Equ c 1 could
bind small hydrophobic molecules similar to those recognized by
mMUP.
-strands A and B folds over
the entrance to the cavity, forming a lid that apparently precludes
ligand access to the putative binding site (Fig. 2). The temperature
factor values of L1 residues are similar to those of the protein core,
and the observed conformation of the loop is stabilized by several
hydrogen bonding interactions (Table II).
Because no residues from this loop are involved in crystal contacts,
the observed closed conformation appears to be an intrinsic property of
Equ c 1, at least under the current crystallization conditions (high
ionic strength, basic pH). Indeed, no substitution was observed in
crystals of Equ c 1 soaked with different lipocalin ligands (histamine,
retinol, retinoic acid, S-
citronellol, methone, 
ionone, benzyl
benzoate, or 3-pyridine-propanol) lending further support to the
hypothesis of a blocked binding site. It is conceivable that more
physiological conditions (i.e. lower ionic strength and/or
more acidic pH) could favor a modification of the L1 loop toward an
"open" conformation allowing the access of ligands to the binding
pocket.
Hydrogen bonding interactions involving residues from the L1 loop
) reacting with
the natural form of Equ c 1 (Table III).
Dissociation constants as measured by ELISA (34) are in the range of
values reported for conventional specific Abs (Table III). Treatment of
Equ c 1 with the reducing compound dithiothreitol did not affect the
binding of mAbs 118, 220, and 65 but abolished the reactivity of mAb
197, suggesting that the epitope recognized by the latter depends on the integrity of the disulfide bridge. Competition experiments in ELISA
(Fig. 4) revealed that mAbs 118 and 197 mutually inhibited each other for binding to natural Equ c 1, indicating that both mAbs recognize overlapping epitopes. However, mAb
220 binds to a different target on the molecular surface, because its
reactivity with natural Equ c 1 was not affected by the presence of
mAbs 118 or 197 (and conversely).
Binding constants of anti-Equ c 1 monoclonal (IgG1,
)
antibodies

View larger version (33K):
[in a new window]
Fig. 4.
Competitive ELISA between three mouse
anti-Equ c 1 mAbs. Natural Equ c 1 (10 µg/ml) was coated on the
microtitration plate, and biotinylated mAbs (1 µg/ml) (*) as
indicated were co-incubated with competitor mAb 118 (open
bar), mAb 197 (hatched bar), or mAb 220 (closed
bar) at 10 µg/ml. Results are expressed as the percentage of
residual biotinylated mAb binding revealed by peroxidase-labeled
streptavidin.
Immunoreactivity of natural and recombinant Equ c 1 and point mutants
of rSLG Equ c 1, as determined by direct ELISA
, <10%; +, between 10% and 50%; ++, between 50% and
75%; +++, >75%. mAbs were tested at 10 µg/ml.

View larger version (15K):
[in a new window]
Fig. 5.
Competitive ELISA between mouse mAbs and
human serum IgE from horse allergic patients. Equ c 1 (10 µg/ml), either natural (A) or recombinant (B),
was coated on a microtitration plate, and IgE serum representative of
eight allergic patients (1/10 dilution) was co-incubated with varying
concentrations of competitor antibody: mAb 118 (
), mAb 197 (
),
mAb 220 (
), mAb 65 (
), or rabbit anti-Equ c 1 polyclonal Abs
(
). Binding of human IgE was detected with biotinylated goat
anti-human IgE Abs followed by peroxidase-coupled streptavidin and
revealed with o-phenylene diamine according to the
manufacturer's recommendations. Results are expressed as the
percentage of inhibition of human IgE binding.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-lactoglobulin), Bla g 4, Can f 1, Can f 2, and Rat n 1. Although
the physiological role of Equ c 1 is not understood, it presumably
relies on the ability of most lipocalins to bind and transport small
hydrophobic molecules. The nature and size of the amino acid residues
defining the internal pocket and the overall structural similarity of
Equ c 1 with Mus m 1 suggest that both allergens could bind similar
types of ligands. In addition, preliminary experiments using affinity
chromatography with histamine-bound agarose gel suggested that Equ c 1 may bind histamine,2 a
mediator released by basophils and mast cells, which plays a crucial
role in allergy. Such a ligand has been described for other lipocalins
like those found in the saliva of the blood-feeding insect
Rhodnius prolixus (37) and Rhipicephalus
appendiculatus ticks (38). However, the specificity of the horse
allergen for histamine needs to be confirmed, because the hydrophilic
nature of the ligand has no counterpart within the hydrophobic binding site of Equ c 1, and soaking trials of Equ c 1 crystals with various lipocalin ligands (including histamine) were inconclusive.

View larger version (54K):
[in a new window]
Fig. 6.
Front and side view of the molecular surface
of the Equ c 1 dimer showing putative IgE and mAb 220 binding targets
(see "Discussion"). Regions near to the positions of the
four amino acid residues substituted by site-directed mutagenesis
(Arg26, Glu82, Lys129, and
Glu148) are shown in red, whereas regions far
away from these sites are in blue. The two putative
glycosylation sites (Asn53 and Asn68) are also
indicated. This figure was produced with the program GRASP (43).
-sheet (strands
A-B-C-D) on the allergen surface (Fig. 6) appears as the most promising candidate for a critical IgE epitope.
-helix). However, the similar reactivity of mAb 220 with nonreduced and reduced Equ c 1 (Table III)
seems to argue against this possibility, because the disruption of the
intramolecular disulfide bridge Cys83-Cys176 is
expected to modify the conformation of the 158-172 segment. Moreover,
an epitope within this region would be confined to the space delimited
by the two Glu148 residues from each monomer (see Fig. 6),
because mAb 220 recognizes the single mutant E148A. Therefore, given
the molecular size of the antibody combining site, the actual epitope
should extend through the dimer interface and could not represent a
common determinant of allergenic lipocalins with different modes of dimerization.
-strand A, the L3
loop, and two highly conserved charged residues (Glu148 and
Glu151 in Equ c 1) in the exposed face of the
-helix.
The binding studies of Equ c 1 reported here provide evidence against
the involvement of the L3 loop and the conserved glutamates in a common
IgE epitope. In contrast, both conserved ends of
-strand A are
exposed to the solvent close to the putative IgE binding targets
identified in our study; the N-terminal end is adjacent to the L2 loop
and the C-terminal end is in contact with residues from the loop
158-172 following the
-helix. These results lend support to the
possible existence of a common critical determinant of allergenicity in lipocalins and suggest putative IgE binding targets of the major horse
allergen for further mutational studies.
![]()
FOOTNOTES
Present address: Dept. of Molecular Biophysics & Biochemistry,
Yale University, 260 Whitney Ave., New Haven, CT 06511.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Dandeu, J. P.,
Rabillon, J.,
Divanovic, A.,
Carmi-Leroy, A.,
and David, B.
(1993)
J. Chromatogr.
621,
23-31
2.
Goubran Botros, H.,
Rabillon, J.,
Gregoire, C.,
David, B.,
and Dandeu, J. P.
(1998)
J. Chromatogr.
710,
57-65
3.
Gregoire, C.,
Rosinski-Chupin, I.,
Rabillon, J.,
Alzari, P. M.,
David, B.,
and Dandeu, J. P.
(1996)
J. Biol. Chem.
271,
32951-32959
4.
Gregoire, C.,
Tavares, G. A.,
Lorenzo, H. K.,
Dandeu, J. P.,
David, B.,
and Alzari, P. M.
(1999)
Acta Crystallogr. Sec. D
55,
880-882
5.
Newcomer, M. E.,
Jones, T. A.,
Åqvist, J.,
Sundelin, J.,
Eriksson, U.,
Rask, L.,
and Peterson, P. A.
(1984)
EMBO J.
3,
1451-1454
6.
Zanotti, G.,
Panzalorto, M.,
Marcato, A.,
Malpeli, G.,
Folli, C.,
and Berni, R.
(1998)
Acta Crystallogr. Sec. D
54,
1049-1052
7.
Bianchet, M. A.,
Bains, G.,
Pelosi, P.,
Pevsner, J.,
Snyder, S. H.,
Monaco, H. L.,
and Amzel, L. M.
(1996)
Nat. Struct. Biol.
3,
934-939
8.
Tegoni, M.,
Ramoni, R.,
Bignetti, E.,
Spinelli, S.,
and Cambillau, C.
(1996)
Nat. Struct. Biol.
3,
863-867
9.
Bocskei, Z.,
Groom, C. R.,
Flower, D. R.,
Wright, C. E.,
Phillips, S. E.,
Cavaggioni, A.,
Findlay, J. B.,
and North, A. C.
(1992)
Nature
360,
186-188
10.
Chaudhuri, B. N.,
Kleywegt, G. J.,
Bjorkman, J.,
Lehman-McKeeman, L. D.,
Oliver, J. D.,
and Jones, T. A.
(1999)
Acta Crystallogr. Sec. D
55,
753-762
11.
Lorusso, J. R.,
Moffat, S.,
and Ohman, J. L., Jr.
(1986)
J. Allergy Clin. Immunol.
78,
928-937
12.
Walls, A. F.,
and Longbottom, J. L.
(1985)
J. Allergy Clin. Immunol.
75,
242-251
13.
Ball, G.,
Shelton, M. J.,
Walsh, B. J.,
Hill, D. J.,
Hosking, C. S.,
and Howden, M. E.
(1994)
Clin. Exp. Allergy
24,
758-764
14.
Arruda, L. K.,
Vailes, L. D.,
Hayden, M. L.,
Benjamin, D. C.,
and Chapman, M. D.
(1995)
J. Biol. Chem.
270,
31196-31201
15.
Konieczny, A.,
Morgenstern, J. P.,
Bizinkauskas, C. B.,
Lilley, C. H.,
Brauer, A. W.,
Bond, J. F.,
Aalberse, R. C.,
Wallner, B. P.,
and Kasaian, M. T.
(1997)
Immunology
92,
577-586
16.
Santa, H.,
Saarela, J. T.,
Laatikainen, R.,
Rautianen, J.,
Virtanen, T.,
Rytkonen, M.,
and Mantyjarvi, R.
(1998)
J. Protein Chem.
17,
657-662
17.
Papiz, M. Z.,
Sawyer, L.,
Eliopoulos, E. E.,
North, A. C.,
Findlay, J. B.,
Sivaprasadarao, R.,
Jones, T. A.,
Newcomer, M. E.,
and Kraulis, P. J.
(1986)
Nature
324,
383-385
18.
Brownlow, S.,
Morais Cabral, J. H.,
Cooper, R.,
Flower, D. R.,
Yewdall, S. J.,
Polikarpov, I.,
North, A. C.,
and Sawyer, L.
(1997)
Structure
5,
481-495
19.
Rouvinen, J.,
Rautiainen, J.,
Virtanen, T.,
Zeiler, T.,
Kauppinen, J.,
Taivainen, A.,
and Mantyjarvi, R.
(1999)
J. Biol. Chem.
274,
2337-2343
20.
Otwinowski, Z.,
and Minor, W.
(1997)
Methods Enzymol.
276,
307-326
21.
Navaza, J.
(1994)
Acta Crystallogr. Sec. A
50,
157-163
22.
Brünger, A. T.,
Kuriyan, J.,
and Karplus, M.
(1987)
Science
235,
458-460
23.
Murshudov, G. N.,
Vagin, A. A.,
and Dodson, E. J.
(1997)
Acta Crystallogr. Sec. D
53,
240-255
24.
Collaborative Computational Project Number 4.
(1994)
Acta Crystallogr. Sec. D
50,
760-763
25.
Jones, T. A.,
Zou, J. Y.,
Cowan, S. W.,
and Kjeldgaard, M.
(1991)
Acta Crystallogr. Sec. A
47,
110-119
26.
Lamzin, V. S.,
and Wilson, K. S.
(1993)
Acta Crystallogr. Sec. D
49,
129-147
27.
Laskowski, R. A.,
MacArthur, M. W.,
Hutchinson, S. C.,
and Thornton, J. M.
(1993)
J. Appl. Crystallogr.
26,
283-291
28.
Flower, D. R.,
North, A. C.,
and Attwood, T. K.
(1993)
Protein Sci.
2,
753-761
29.
Flower, D. R.
(1996)
Biochem. J.
318,
1-14
30.
Cowan, S. W.,
Newcomer, M. E.,
and Jones, T. A.
(1990)
Proteins Struct. Funct. Genet.
8,
44-61
31.
Coles, M.,
Diercks, T.,
Muehlenweg, B.,
Bartsch, S.,
Zolzer, V.,
Tschesche, H.,
and Kessler, H.
(1999)
J. Mol. Biol.
289,
139-157
32.
Huber, R.,
Schneider, M.,
Mayr, I.,
Muller, R.,
Deutzmann, R.,
Suter, F.,
Zuber, H.,
Falk, H.,
and Kayser, H.
(1987)
J. Mol. Biol.
198,
499-513
33.
Kabsch, W.,
and Sander, C.
(1983)
Biopolymers
22,
2577-2637
34.
Friguet, B.,
Chaffotte, A. F.,
Djavadi-Ohaniance, L.,
and Goldberg, M. E.
(1985)
J. Immunol. Methods
77,
305-319
35.
Laver, W. G.,
Air, G. M.,
Webster, R. G.,
and Smith-Gill, S. J.
(1990)
Cell
61,
553-556
36.
Musu, T.,
Grégoire, C.,
David, B.,
and Dandeu, J. P.
(1997)
Clin. Rev. Allergy Immunol.
15,
485-498
37.
Ribeiro, J. M.,
and Walker, F. A.
(1994)
J. Exp. Med.
180,
2251-2257
38.
Paesen, G. C.,
Adams, P. L.,
Harlos, K.,
Nuttall, P. A.,
and Stuart, D. I.
(1999)
Mol. Cell
3,
661-671
39.
Olson, J. R.,
and Klapper, D. G.
(1986)
J. Immunol.
136,
2109-2115
40.
Zeiler, T.,
Mantyjarvi, R.,
Rautiainen, J.,
Rytkonen-Nissinen, M.,
Vilja, P.,
Taivainen, A.,
Kauppinen, J.,
and Virtanen, T.
(1999)
J. Immunol.
162,
1415-1422
41.
Virtanen, T.,
Zeiler, T.,
Rautiainen, J.,
and Mäntyjärvi, R.
(1999)
Immunol. Today
20,
398-200
42.
Kraulis, P. J.
(1991)
J. Appl. Crystallogr.
24,
946-950
43.
Nicholls, A.,
Sharp, K.,
and Honig, B.
(1991)
Proteins Struct. Funct. Genet.
11,
281-296
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
M. Li, A. Gustchina, J. Alexandratos, A. Wlodawer, S. Wunschmann, C. L. Kepley, M. D. Chapman, and A. Pomes Crystal Structure of a Dimerized Cockroach Allergen Bla g 2 Complexed with a Monoclonal Antibody J. Biol. Chem., August 15, 2008; 283(33): 22806 - 22814. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Chan, S. T. Ong, S. Y. Ong, F. T. Chew, and Y. K. Mok Nuclear magnetic resonance structure-based epitope mapping and modulation of dust mite group 13 allergen as a hypoallergen. J. Immunol., April 15, 2006; 176(8): 4852 - 4860. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Scholl, N. Kalkura, Y. Shedziankova, A. Bergmann, P. Verdino, R. Knittelfelder, T. Kopp, B. Hantusch, C. Betzel, K. Dierks, et al. Dimerization of the Major Birch Pollen Allergen Bet v 1 Is Important for its In Vivo IgE-Cross-Linking Potential in Mice J. Immunol., November 15, 2005; 175(10): 6645 - 6650. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Trevino, M. F. Garcia-Mayoral, P. Barral, M. Villalba, J. Santoro, M. Rico, R. Rodriguez, and M. Bruix NMR Solution Structure of Ole e 6, a Major Allergen from Olive Tree Pollen J. Biol. Chem., September 10, 2004; 279(37): 39035 - 39041. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nespoulous, L. Briand, M.-M. Delage, V. Tran, and J.-C. Pernollet Odorant Binding and Conformational Changes of a Rat Odorant-binding Protein Chem Senses, March 1, 2004; 29(3): 189 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. H. Greene, E. D. Chrysina, L. I. Irons, A. C. Papageorgiou, K. R. Acharya, and K. Brew Role of conserved residues in structure and stability: Tryptophans of human serum retinol-binding protein, a model for the lipocalin superfamily Protein Sci., November 1, 2001; 10(11): 2301 - 2316. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||